GT Biopharma, Inc.

Nasdaq:GTBP

Pharmaceutical Preparations·SAN FRANCISCO, CA

CEO

Breen Michael Martin

CFO

Urban Alan Louis

Financials

20 shown

Type	Period	Ended	Filed
10-Q/A	Q2 2025	6/30/25	3/6/26	→
10-Q/A	Q3 2025	9/30/25	3/6/26	→
10-K	FY 2025	12/31/25	3/2/26	→
10-Q	Q3 2025	9/30/25	11/14/25	→
10-Q	Q2 2025	6/30/25	8/14/25	→
10-Q	Q1 2025	3/31/25	5/15/25	→
↓

Earnings Releases (8-K)

2 shown

Filed	Period
11/14/25	Q4 FY2025	→
11/15/18	Q4 FY2018	→

News (8-K)

78 shown

Filed	Type	Description
3/2/26	Restatement	Non-Reliance on Previously Issued Financial Statements	→
11/26/25	Delisting	Notice of Delisting or Failure to Satisfy a Continued Listing Rule	→
9/26/25	Other	Material Modification to Rights of Security Holders	→
9/23/25	Other	Material Modification to Rights of Security Holders	→
8/29/25	Exec Change	Departure or Appointment of Directors or Certain Officers	→
7/24/25	Vote	Submission of Matters to a Vote of Security Holders	→
↓

Prospectuses & Registrations

40 shown

Filed	Form	Description
1/30/26	424B3	424B3	→
1/21/26	S-1	S-1	→
1/8/26	424B3	424B3	→
12/2/25	424B3	424B3	→
10/24/25	S-1	S-1	→
7/3/25	424B3	424B3	→
↓

Filing History(856 filings)

TypeDateAccessionPeriodSize

10-Q/A

Mar 6, 2026

0001493152-26-00912710-Q/A

Jun 30, 2025

7.9 MB

10-Q/A

Mar 6, 2026

0001493152-26-00912610-Q/A

Sep 30, 2025

7.1 MB

10-K

Mar 2, 2026

0001493152-26-00844310-K

Dec 31, 2025

8.5 MB

8-K

Mar 2, 2026

0001493152-26-0084428-K

Mar 1, 2026

273.8 KB

EFFECT

Jan 30, 2026

9999999995-26-000420

—

2.0 KB

424B3

Jan 30, 2026

0001493152-26-004547424B3

—

339.7 KB

S-1

Jan 21, 2026

0001493152-26-003089S-1

—

972.2 KB

424B3

Jan 8, 2026

0001493152-26-000976424B3

—

10.0 KB

EFFECT

Dec 2, 2025

9999999995-25-003476

—

2.0 KB

424B3

Dec 2, 2025

0001493152-25-025796424B3

—

307.0 KB

8-K

Nov 26, 2025

0001493152-25-0251628-K

Nov 20, 2025

202.8 KB

10-Q

Nov 14, 2025

0001493152-25-02340010-Q

Sep 30, 2025

6.2 MB

8-K

Nov 14, 2025

0001493152-25-0226318-K

Nov 14, 2025

233.2 KB

S-1

Oct 24, 2025

0001493152-25-019296S-1

—

1.1 MB

8-K

Sep 26, 2025

0001493152-25-0157258-K

Sep 25, 2025

199.4 KB

8-K

Sep 23, 2025

0001493152-25-0146848-K

Sep 17, 2025

217.5 KB

Sep 8, 2025

0001641172-25-026893

Sep 4, 2025

5.5 KB

Sep 8, 2025

0001641172-25-026890

Sep 4, 2025

9.9 KB

Sep 8, 2025

0001641172-25-026894

Sep 4, 2025

7.7 KB

Sep 8, 2025

0001641172-25-026891

Sep 4, 2025

5.4 KB

Sep 8, 2025

0001641172-25-026892

Sep 4, 2025

5.5 KB

8-K

Aug 29, 2025

0001493152-25-0124798-K

Aug 26, 2025

225.2 KB

10-Q

Aug 14, 2025

0001493152-25-01197110-Q

Jun 30, 2025

7.1 MB

Jul 30, 2025

0001641172-25-021546

Jun 10, 2025

3.2 KB

8-K

Jul 24, 2025

0001641172-25-0208478-K

Jul 24, 2025

220.9 KB

25 filings shown

Filed	Form	Description
6/11/25	DEFA14A	DEFA14A	→
6/11/25	DEF 14A	DEF 14A	→
5/30/25	PRE 14A	PRE 14A	→
6/17/24	DEFA14A	DEFA14A	→
4/29/24	DEFA14A	DEFA14A	→
4/29/24	DEF 14A	DEF 14A	→
↓

GT Biopharma, Inc.

Financials

Earnings Releases (8-K)

News (8-K)

Prospectuses & Registrations

Filing History(856 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
9/8/25	4	4	→
9/8/25	4	4	→
9/8/25	4	4	→
9/8/25	4	4	→
9/8/25	4	4	→
7/30/25	3	3	→
↓